

**MEETING MINUTES  
OF THE  
CENTERS FOR MEDICARE AND MEDICAID SERVICES  
MEDICARE EVIDENCE DEVELOPMENT & COVERAGE  
ADVISORY COMMITTEE**

**April 21, 2010**

**Centers for Medicare and Medicaid Services  
7500 Security Boulevard  
Baltimore, Maryland**

**Medicare Evidence Development & Coverage Advisory Committee**

**April 21, 2010**

**Attendees**

Clifford Goodman, Ph.D.  
Chairperson

Saty Satya-Murti, M.D., F.A.A.N.  
Vice-Chairperson

Maria A. Ellis  
Executive Secretary

Voting Members

Charles S. Carignan, M.D.  
Roger Dmochowski, M.D.  
Josef E. Fischer, M.D.  
James M. Hevezi, Ph.D., FACR/FAAPM  
Jeffrey G. Jarvik, M.D., M.P.H.  
Roger D. Klein, M.D., J.D.  
Barbara McNeil, M.D., Ph.D.  
Curtis A. Mock, M.D., M.B.A.  
Louis Potters, M.D., FACR  
David J. Samson, M.S.  
Sanford J. Schwartz, M.D.  
Robert L. Steinbrook, M.D.  
Craig Umscheid, M.D., M.S.C.E.

Industry Representative

G. Gregory Raab, Ph.D.

CMS Liaison

Marcel Salive, M.D.

**Wednesday, April 21, 2010, 8:10 a.m.**

The Medicare Evidence Development & Coverage Advisory Committee met on April 21, 2010, to discuss the evidence, hear presentations and public comment, and make recommendations concerning currently available evidence on the risks, benefits and outcomes of radiation therapy inclusive of external beam radiotherapy and brachytherapy for the treatment of localized prostate cancer.

The meeting began with a reading of a conflict of interest statement, welcoming remarks, and an introduction of the Committee.

**CMS Presentation and Voting Questions.** After a welcome by the division director, a CMS representative presented the panel and audience with the questions that would be considered before being voted on or discussed by the panel.

**Presentation of Technology Assessment.** The panel heard a presentation from three members of the Evidence-Based Practice Center at Tufts University concerning their technology assessment update performed under contract to AHRQ. Following the presentation, there was a limited time for the panelists to question the presenters before moving on to public comments.

**Scheduled Public Comments.** The panel heard from a total of 11 scheduled speakers, including clinicians, researchers, industry and professional society representatives, and patient advocates.

**Open Public Comments.** The panel heard from 15 members of the public, including private practitioners, researchers, prostate cancer patients, and patient advocacy representatives.

**Questions to Presenters.** The panel was given the opportunity to pose questions to the presenters.

**Initial Open Panel Discussion.** The panel conducted an extensive discussion on each of the voting questions posed by CMS. The discussion included input from the chair, members of the panel, and presenters as requested by members of the panel.

**Formal Remarks and Voting Questions.** The panel turned its attention to the voting questions, having limited additional discussion before votes on each question. As a result of these discussions, consensus was reached that as to questions two and three, watchful waiting would include no treatment as well as active surveillance. The results of the voting were displayed to the public on cards and recorded by staff.

**Final Open Panel Discussion.** After resolution of the voting questions, the panel discussed questions six and seven, the non-voting questions. At the conclusion of those discussions, each panelist was allowed and encouraged to give a statement summarizing

their perspectives regarding the quality of the available evidence and how current evidence gaps might be addressed.

**Adjournment.** The meeting adjourned at 3:05 p.m.

I certify that I attended the meeting  
of the Medicare Evidence Development  
& Coverage Advisory Committee on  
April 21, 2010, and that these minutes  
accurately reflect what transpired.

  
\_\_\_\_\_  
Maria A. Ellis  
Executive Secretary, MEDCAC, CMS

I approve the minutes of this meeting  
as recorded in this summary.



---

Clifford Goodman, Ph.D.  
Chairperson